ArticleClinical and experimental medicine2025

Treatment of refractory non-small cell lung cancer with combined infusion of modified CIK cells and PD1 antibody: safety and efficacy.

Feiyu Yun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.